Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D. Wiviott, Marc S. Sabatine, Deepak L. Bhatt et al.|New England Journal of Medicine|2018Cited by 6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseMarc S. Sabatine, Terje R. Pedersen, Robert P. Giugliano et al.|New England Journal of Medicine|2017Cited by 6k
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery DiseaseMarc P. Bonaca, Marc S. Sabatine, Patrice Nault et al.|Circulation|2017Cited by 754
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S. Sabatine, Terje R. Pedersen, Lawrence A. Leiter et al.|The Lancet Diabetes & Endocrinology|2017Cited by 595
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseMichelle L. O’Donoghue, Marc S. Sabatine, Robert S. Rosenson et al.|New England Journal of Medicine|2022Cited by 513